Fritextsökning
Artiklar per år
Innehållstyper
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other industries for inspiration and knowledge.
-
Ranking: Top 10 highest-paid CEOs in pharma
It's nice to hear that things go well for others, right? Some of those who have done really well – at least financially – are listed here in the ranking of the best paid CEOs in Big Pharma 2023.
-
Danish obesity success causes recruitment problems in southern Sweden
The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.
-
Life science-staden Göteborg – Vi är ”Lilla Boston”
I Västsverige satsar man på life science inom alltifrån avancerade terapiläkemedel till femtech. Samtidigt blickar aktörerna mot andra branscher för inspiration och kunskap.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what constitutes ‘fine research’.
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
Xbrane i amerikanskt licensavtal
Bioteknikbolaget Xbrane Biopharma och tyska läkemedelsbolaget Stada har ingått ett licensavtal för de amerikanska kommersiella rättigheterna till biosimilarkandidaten för ranibizumab till Valorum.
-
Astra Zeneca's Covid-19 vaccine Vaxzevria is being withdrawn worldwide
AstraZeneca initiates a worldwide withdrawal of its Covid vaccine Vaxzevria. The measure is taken just months after the company admitted the vaccine can cause a rare and dangerous side effect, but AstraZeneca claims that the decision is purely commercial.
-
Christina Östberg Lloyd satsar på eget – ”Jag är full av energi”
Efter över tjugo år på olika tjänster inom life science-företag satsar Christina Östberg Lloyd på eget som konsult. ”Detta öppnar upp helt nya perspektiv och möjligheter”, säger hon till Life Science Sweden.
-
Carl Borrebaeck – professor och serieentreprenör med känsla för fart
Prisbelönt cancerforskare, grundare av en hel drös börsbolag, ständigt i den akademiska och kommersiella hetluften under flera decennier. Men Carl Borrebaeck, professor i immunteknologi i Lund, är inte nöjd än. ”Vi har ett nytt, potentiellt superspännande projekt på gång”, säger han.
-
List: The coolest names in biotech
Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuticals, a Swedish, or at least Swedish-British, drug came out on top.
-
Svensk smärtapp får patent i Europa
Lundbaserade Paindrainer har beviljats europeiskt patent för sin AI-baserade plattform för hantering av kronisk smärta.
-
The Covid pandemic accelerated the development of cancer vaccine
The Covid pandemic gave a major boost to the vaccine field. The Danish biotech company Expres2ion Biotechnologies, which is developing a vaccine against breast cancer, testifies to this.
-
Specific proposals and targets top the universities’ desired priorities
What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Karolinska Institutet and Sahlgrenska Academy.
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic region with vaccines during a future pandemic. These are some of the projects underway at NorthX Biologics – under the direction of new CEO Janet Hoogstraate.
-
KI’s new super machine measures brain activity in real-time – “A very expensive hairdo”
Using brand-new, super-advanced equipment, researchers at Karolinska Institutet can now measure brain activity in real-time, with higher resolution than previously possible. “This opens up fantastic opportunities”, says brain researcher Daniel Lundqvist.
-
Decades of research destroyed at KI – a hacker attack cannot be ruled out!
Years of research, together with half a billion Swedish krona, went up in smoke when the freezers at Karolinska Institutet overheated. The breakdown has now been reported to the police.
-
Ingrid Lönnstedt: Demystification of the power of a scientific study
”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess the magnitude of the treatment effect before performing the study?” writes Ingrid Lönnstedt in a column.
-
”Information security must become part of the Swedish life science strategy”
Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.
-
Nytt scale up-program för life science-företag startar i Sydsverige
Inkubatorn Smile tillsammans med Medicon Village vill hjälpa bolag att nå sin fulla potential. Nu har de startat ett scale up-program för etablerade life science-företag.
-
Ny vd på Wntresearch
Malmöbaserade Wntreserach har anställt en ny vd. Per Norlén tar över stafettpinnen efter Pernilla Sandwall som varit vd för bolaget sedan 2022.
-
Ingrid Lönnstedt: What does the p-value mean?
The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significance level. But what does that mean? Read Ingrid Lönnstedt´s column to learn more.
BREAKING